Geron Corporation
GERN
NASDAQ3.25
Geron Corporation
NASDAQ:GERN
RECENT
PRICE
3.25
P/E
RATIO
-8.37
(PEG:- -)
P/E RATIO
RELATIVE
TO S&P
-0.40
DIV
YLD
0.00%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
0.78 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 05/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Fiscal year
0.05
(0.47)
(0.41)
- -
0.10
(0.49)
(0.40)
- -
0.04
(0.79)
(0.57)
- -
0.02
(0.80)
(0.51)
- -
0.04
(1.14)
(0.46)
0.00
0.02
(0.78)
(0.51)
- -
0.02
(0.54)
(0.44)
- -
0.01
(0.30)
(0.29)
- -
0.01
(0.23)
0.06
- -
0.23
0.00
(0.15)
- -
0.04
(0.19)
(0.12)
- -
0.01
(0.18)
(0.13)
- -
0.01
(0.15)
(0.12)
- -
0.00
(0.36)
(0.23)
- -
0.00
(0.28)
(0.25)
- -
0.00
(0.35)
(0.29)
- -
0.00
(0.36)
(0.31)
- -
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.01
2.63
0.04
2.77
0.03
2.15
0.02
1.96
0.01
1.97
0.00
1.18
0.01
0.67
0.00
0.47
0.00
0.85
0.00
0.90
0.00
0.77
- -
0.65
0.00
1.01
0.00
0.71
0.00
0.78
0.00
0.39
0.00
0.32
CAPEX per share
Book Value per share
66
74
78
88
98
125
127
128
154
158
159
159
177
190
271
328
368
Comm.Shares outs.(m)
- -
- -
- -
(15.2)
(0.9)
- -
(5.4)
(0.3)
- -
(7.9)
(0.1)
- -
(4.9)
(0.2)
0.0%
(4.7)
(0.3)
- -
(3.2)
(0.2)
- -
(8.0)
(0.5)
- -
(12.9)
(0.7)
- -
12,952.1
647.0
- -
(14.4)
(0.7)
- -
(13.3)
(0.6)
- -
(20.8)
(0.8)
- -
(4.0)
(0.2)
- -
(5.8)
(0.2)
- -
(4.4)
(0.1)
- -
(8.4)
(0.4)
- -
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (30/9/22 | Q3)
Total liabilities
$124 m.
Total assets
$233 m.
Long-term debt
$42 m.
Cash and equiv.
$61 m.
Goodwill - -
Retained earnings $(1,371) m.
Common stock 405 m. shares
Market Capitalisation
$1,204 m. (as of 28/5/23)
2
(3,942.4)%
3
(2,648.9)%
1
(3,036.5)%
1
(3,149.3)%
36
(1.5)%
6
(497.3)%
1
(2,746.9)%
1
(2,914.9)%
0
(15,762.0)%
0
(30,400.4)%
1
(8,183.7)%
2
(19,516.5)%
Revenue (m)
Operating margin
2
(97)
1
(69)
0
(38)
0
(36)
0
0
0
(30)
0
(28)
0
(27)
1
(69)
1
(76)
1
(116)
1
(131)
Depreciation (m)
Net profit (m)
- -
(3,972.6)%
- -
(2,542.7)%
- -
(2,991.3)%
- -
(3,093.7)%
- -
0.1%
- -
(479.3)%
- -
(2,621.2)%
- -
(2,534.4)%
- -
(14,901.7)%
- -
(29,888.1)%
- -
(8,335.4)%
- -
(19,971.7)%
Income tax rate
Net profit margin
112
- -
147
84
- -
86
59
- -
60
112
- -
131
109
- -
142
108
- -
122
89
- -
104
159
- -
178
113
- -
135
169
24
211
142
54
126
139
42
108
Working capital (m)
Long-term debt (m)
Equity (m)
- -
(60.4)%
(66.1)%
(80.1)%
(68.8)%
(80.4)%
(64.1)%
(56.9)%
(64.2)%
(27.2)%
(20.6)%
(27.3)%
0.1%
0.1%
0.0%
(24.1)%
(22.6)%
(24.1)%
(26.8)%
(25.2)%
(26.9)%
(15.2)%
(14.6)%
(15.2)%
(49.9)%
(41.4)%
(50.7)%
(31.2)%
(27.7)%
(35.8)%
(62.3)%
(49.7)%
(91.8)%
(83.6)%
(53.9)%
(121.4)%
ROIC
Return on capital
Return on equity
Working Capital
2019
2020
2021
Cash assets
139
136
161
Receivables
1
1
2
Inventory
- -
- -
- -
Other
1
3
2
Current assets
142
200
187
Acc. Payable
1
7
7
Debt due
0
1
1
Other
27
23
38
Current liab.
28
31
46
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
10.6%
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
Plowback ratio
Div.&Repurch. to FCF
Geron Corporation (US) started trading on July 3, 1996 (cik: 0000886744), operates in the Healthcare sector (Biotechnology industry), has 98 full-time employees, and is led by Dr. John A. Scarlett M.D.. Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
87.21%
352.75%
Cash flow
51.77%
-36.51%
Earnings
53.59%
-7139.27%
Dividends
- -
- -
Book value
15.82%
14.60%
Insider trading
Type
Shares
Date
Scarlett John A
Award
1.75mln.
02/22/23
Bloom Olivia Kyusuk
Award
575,000
02/22/23
Feller Faye
Award
540,000
02/22/23
Grethlein Andrew J
Award
780,000
02/22/23
Kapur Anil
Award
625,000
02/22/23
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
0
0
0
0
0
2021
0
0
0
1
1
2022
0
0
0
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
(0.06)
(0.06)
(0.07)
(0.09)
-0.28
2021
(0.08)
(0.09)
(0.08)
(0.10)
-0.35
2022
(0.09)
(0.07)
(0.10)
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
06/18/2021
Adobe, Smith & Wesson, Orphazyme: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...